Impact of PIVC Length and Gauge on Catheter Indwell Time

Not Applicable

Completed

• Conditions: Indication for Peripheral Intravenous Catheterisation
• Interventions: Device: Peripheral Intravenous Catheter

• Registration Number: NCT04344314
• Lead Sponsor: Becton, Dickinson and Company

Brief Summary

This is a single-centre, open-label, multi-visit study design, in 40 healthy participants, randomized by gauge of peripheral intravenous catheter (PIVC) device into the lower arm cephalic vein of both arms.

The purpose of this study is to assess impact of catheter length and gauge on PIVC indwell time over a 72 hour period. This study will also evaluate the incidence of haemolysis using blood draws from the PIVC.

Detailed Description

The study aims to provide preliminary information on the performance of the peripheral intravenous catheter (PIVC) device,

* assess how blood collection through different catheters over time effects device performance, and

* assess the quality of the blood that is collected through those catheters. Four variations of the Becton Dickinson (BD) Nexiva PIVC will be used in this study. Participants will be randomised by gauge of peripheral intravenous catheter (PIVC) device into the lower arm cephalic vein of both arms. PIVC indwell time will be monitored up to 72 hrs (removal at 72 hrs or upon inability to flush/aspirate). Blood will be collected Day 1 throughout the remainder of indwell time.

Each participant will complete 6 visits: a Screening Visit (V1), PIVC in situ (V2-V5) and follow-up (V6).

The in-situ catheter positions will be compared to the expected tip position based on the catheter lengths. Blood collected will be analysed for haemolysis.

As both device length and gauge are expected to influence haemolysis the study design enables evaluation of both design features.

Study Timeline

• Study First Submitted: 2020-04-07
• Study First Submitted QC: 2020-04-10
• Study First Posted: 2020-04-14
• Study Start: 2020-08-31
• Primary Completion: 2021-03-12
• Study Completion: 2021-03-12
• Results First Submitted: 2022-01-20
• Status Verified: 2023-07
• Results First Submitted QC: 2024-05-08
• Last Update Submitted: 2024-05-08
• Results First Posted: 2024-05-16
• Last Update Posted: 2024-05-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Female or Male
• 18-65 years of age
• Not pregnant at time of recruitment within 48 hrs Day 1 procedures (self-reported)
• Normal coagulation results (prothrombin time 13-17 sec; activated partial thromboplastin time 27-37 sec)
• Normal platelet aggregation results for Adenosine DiPhosphate (ADP), Thrombin Receptor Activating Peptide (TRAP), and collagen induced maximal amplitude (>70% amplitude over 6 mins)
• Target cephalic veins readily cannulatable (i.e., ≥ ~2.55 mm to obtain C/V ratio less than 45% as indicated by standard 52 of the Intraevenous Nursing Standards (INS) guidelines
• Able and willing to provide verbal and written consent
• Must be an Australian citizen with current Medicare card

Read More

Exclusion Criteria

• History of pro coagulative state/condition (e.g. previous deep vein thrombosis
• Current hypertension (e.g., systolic >139 OR diastolic >89 mmHg)
• Currently on any anti-coagulant or platelet inhibitor medication. Use of NSAIDs and aspirin will be documented however not exclusionary.
• Hemophilia or any current or history of bleeding disorder or tendency
• Presence or report of current blood borne disease/infection (e.g. hepatitis, HIV, leukemia, lymphoma)
• Difficult vascular access (i.e., vein must be readily palpable and cannulatable - no less than ~2.55 mm diameter to maintain ≤45% C/V ratio) as indicated by standard 52 of the INS guidelines
• Allergy or sensitivity to chlorhexidine gluconate, isopropyl alcohol, latex, or skin adhesives
• BMI <18.5 kg/m2 or ≥35 kg/m2
• Positive results for the urine drug screen at screening or check-in (including opiates, methadone, cocaine, amphetamines)
• History or presence of alcoholism (self-reported) or drug abuse within the past 2 years
• A current or previous medical, physical, mental/cognitive disorders or anatomical conditions that, in the opinion of the investigator, would place the patient at risk, would make them unable to perform study procedures or has the potential to confound interpretation of the study results. (e.g., musculo-skeletal injury, chronic back pain)
• Employed by Becton Dickinson, Teleflex Medical, Smiths Medical or B Braun (conflict of interest)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Large gauge arm	Peripheral Intravenous Catheter	2 PIVCs of same gauge (20G) and different lengths
Small gauge arm	Peripheral Intravenous Catheter	2 PIVCs of same gauge (22G) and different lengths

Primary Outcome Measures

Name	Time	Method
Patent Indwell Time Between PIVCs of Different Length and Gauge.	72 hrs	Catheter indwell time for each PIVC, expressed in hours

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Haemolysis Occurrence Based on Blood Collection Device and Catheter Device Configuration	72 hrs	Haemolysis: Frequency of occurrence

Trial Locations

Locations (1)

Griffith University; 🇦🇺 Gold Coast, Queensland, Australia